How To Use CPT Code 0239U

CPT 0239U describes a targeted genomic sequence analysis panel for solid organ neoplasms using cell-free DNA. This article will cover the official description, procedure, qualifying circumstances, appropriate usage, documentation requirements, billing guidelines, historical information, and examples.

1. What is CPT Code 0239U?

CPT 0239U can be used to describe a specific lab test called FoundationOne® Liquid CDx from Foundation Medicine Inc. This test analyzes cell-free DNA from a blood specimen to evaluate at least 311 genes associated with solid-organ tumors. It uses next-generation sequencing technology to identify variants such as substitutions, insertions, deletions, rearrangements, and copy number variations.

2. Official Description

The official description of CPT code 0239U is: ‘Targeted genomic sequence analysis panel, solid organ neoplasm, cell-free DNA, analysis of 311 or more genes, interrogation for sequence variants, including substitutions, insertions, deletions, select rearrangements, and copy number variations.’

3. Procedure

1. The lab analyst processes a blood specimen from a cancer patient to isolate circulating cell-free DNA.
2. The test uses next-generation sequencing with high throughput hybrid-capture technology to evaluate at least 311 genes for sequence variants, including substitutions, insertions, deletions, select rearrangements, and copy number variations.
3. The test results provide clinicians with tumor mutation profiling and information on specific targeted therapies for solid tumors.

4. Qualifying circumstances

CPT 0239U is used for patients with solid organ neoplasms who require genomic sequence analysis of cell-free DNA. It is ordered by clinicians to identify specific therapies and guide treatment options for conditions such as non-small cell lung cancer and prostate cancer. The test is performed on a blood specimen and requires at least 311 genes to be analyzed for sequence variants.

5. When to use CPT code 0239U

CPT code 0239U should be used when ordering the FoundationOne® Liquid CDx test from Foundation Medicine Inc. This test is specifically designed for the analysis of cell-free DNA from a blood specimen for solid organ neoplasms. It should not be used for testing performed on formalin-fixed paraffin-embedded tissue specimens.

6. Documentation requirements

To support a claim for CPT 0239U, the following documentation is required:

• Indication for the test, such as a diagnosis of solid organ neoplasm
• Documentation of the specific test performed, including the use of FoundationOne® Liquid CDx
• Date of service and specimen collection
• Results of the test, including sequence variants, substitutions, insertions, deletions, rearrangements, and copy number variations
• Signature of the lab analyst who performed the test

7. Billing guidelines

When billing for CPT 0239U, ensure that the test is performed by Foundation Medicine Inc. using the FoundationOne® Liquid CDx. Report one unit of this code for each specimen analyzed on a single date of service. It is important to note that some payers may separately reimburse for specimen collection, so it is advisable to check with the appropriate payer for their specific guidelines.

8. Historical information

CPT 0239U was added to the Current Procedural Terminology system on January 1, 2021. As a Proprietary Laboratory Analyses (PLA) code, it is specific to the FoundationOne® Liquid CDx test offered by Foundation Medicine Inc.

9. Examples

1. A patient with non-small cell lung cancer undergoes the FoundationOne® Liquid CDx test to identify targeted therapies based on genomic sequence analysis of cell-free DNA.
2. A clinician orders the FoundationOne® Liquid CDx test for a patient with prostate cancer to determine the most effective treatment options based on genomic profiling.
3. A blood specimen from a patient with a solid organ neoplasm is analyzed using the FoundationOne® Liquid CDx test to identify specific sequence variants and guide personalized treatment decisions.
4. The FoundationOne® Liquid CDx test is performed on a blood sample from a patient with a solid organ neoplasm to evaluate copy number variations and select rearrangements for targeted therapy selection.
5. A clinician utilizes the FoundationOne® Liquid CDx test to analyze cell-free DNA from a blood specimen and identify sequence variants associated with solid organ tumors, aiding in treatment decision-making for a patient.
6. Genomic sequence analysis of cell-free DNA using the FoundationOne® Liquid CDx test is performed on a blood specimen from a patient with a solid organ neoplasm, providing valuable information on potential therapeutic options.
7. A patient with a solid organ neoplasm undergoes the FoundationOne® Liquid CDx test, which analyzes cell-free DNA from a blood specimen to identify sequence variants and copy number variations associated with targeted therapies.
8. The FoundationOne® Liquid CDx test is ordered for a patient with a solid organ neoplasm, providing comprehensive genomic profiling of cell-free DNA to guide treatment decisions.
9. A clinician utilizes the FoundationOne® Liquid CDx test to analyze cell-free DNA from a blood specimen, identifying sequence variants and select rearrangements associated with solid organ tumors and potential targeted therapies.
10. Genomic sequence analysis of cell-free DNA using the FoundationOne® Liquid CDx test is performed on a blood specimen from a patient with a solid organ neoplasm, aiding in the identification of potential therapeutic options.